Opportunities for Improving the Translational Safety of ADCs From NHPs to Humans

9:05 am - Monday 8th March 2027

  • Identifying which toxicities are reasonably predictable from animal or in vitro studies
  • Discussing toxicities that are still difficult to understand and where things are “falling apart”
  • Exploring what can be done to further enhance the understanding of ADC toxicities, including focusing on key toxicities such as ocular and lung regions

Speakers:

President & Chief Executive Officer
Bionavigen Oncology